DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 12, 2013, Pages 3093-3103

  Wartlick, Friedrich ^a   Bopp, Anita ^a   Henninger, Christian ^a   Fritz, Gerhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

DNA damage response; Rac family small GTPase; Topoisomerase II poisons

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EHT 1864; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; POISON; PROTEIN KINASE INHIBITOR; PROTEIN P53; RAC PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATTENUATION; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; EMBRYO; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN PHOSPHORYLATION; RAT; WILD TYPE;

EID: 84884375366     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.08.016     Document Type: Article

References (62)

1. Aznar S., Lacal J.C. Rho signals to cell growth and apoptosis. Cancer Lett. 2001, 165:1-10.
2. Bokoch G.M. Regulation of cell function by Rho family GTPases. Immunol. Res. 2000, 21:139-148.
3. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
4. Minden A., Lin A., Claret F.X., Abo A., Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995, 81:1147-1157.
5. Coso O.A., Chiariello M., Yu J.C., Teramoto H., Crespo P., Xu N., Miki T., Gutkind J.S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995, 81:1137-1146.
6. Jefferies C.A., O'Neill L.A. Rac1 regulates interleukin 1-induced nuclear factor kappaB activation in an inhibitory protein kappaBalpha-independent manner by enhancing the ability of the p65 subunit to transactivate gene expression. J. Biol. Chem. 2000, 275:3114-3120.
7. Canman C.E., Kastan M.B. Three paths to stress relief. Nature 1996, 384:213-214.
8. Aznar S., Fernandez-Valeron P., Espina C., Lacal J.C. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 2004, 206:181-191.
9. Fritz G., Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr. Cancer Drug Targets 2006, 6:1-14.
10. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr. Cancer Drug Targets 2009, 9:626-638.
11. Haydont V., Bourgier C., Pocard M., Lusinchi A., Aigueperse J., Mathe D., Bourhis J., Vozenin-Brotons M.C. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin. Cancer Res. 2007, 13:5331-5340.
12. Huelsenbeck J., Henninger C., Schad A., Lackner K.J., Kaina B., Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011, 2:e190.
13. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
14. Rao S., Lowe M., Herliczek T.W., Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998, 17:2393-2402.
15. Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005, 26:883-891.
16. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999, 5:221-225.
17. Graaf M.R., Richel D.J., van Noorden C.J., Guchelaar H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 2004, 30:609-641.
18. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int. J. Oncol. 2005, 27:1401-1409.
19. Fromigue O., Hamidouche Z., Marie P.J. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J. Biol. Chem. 2008, 283:30549-30556.
20. Zhou Q., Liao J.K. Pleiotropic effects of statins - basic research and clinical perspectives. Circ. J. 2010, 74:818-826.
21. Nitiss J.L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr. Opin. Investig. Drugs 2002, 3:1512-1516.
22. Smart D.J., Halicka H.D., Schmuck G., Traganos F., Darzynkiewicz Z., Williams G.M. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res. 2008, 641:43-47.
23. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell 2007, 28:739-745.
24. Olive P.L. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol. 2004, 75:355-373.
25. Roos W.P., Kaina B. DNA damage-induced apoptosis: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2012, 332:237-248.
26. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
27. Kremer L.C., van Dalen E.C., Offringa M., Ottenkamp J., Voute P.A. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol. 2001, 19:191-196.
28. Ferreira A.L., Matsubara L.S., Matsubara B.B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6:278-281.
29. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin. Drug Saf. 2005, 4:219-234.
30. Azarova A.M., Lyu Y.L., Lin C.P., Tsai Y.C., Lau J.Y., Wang J.C., Liu L.F. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11014-11019.
31. Lyu Y.L., Kerrigan J.E., Lin C.P., Azarova A.M., Tsai Y.C., Ban Y., Liu L.F. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007, 67:8839-8846.
32. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18:1639-1642.
33. Ma J., Wang Y., Zheng D., Wei M., Xu H., Peng T. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways. Cardiovasc. Res. 2013, 97:77-87.
34. Damrot J., Nuebel T., Epe B., Roos W.P., Kaina B., Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 2006, 149:988-997.
35. Mahmoudi M., Gorenne I., Mercer J., Figg N., Littlewood T., Bennett M. Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ. Res. 2008, 103:717-725.
36. Fritz G., Henninger C., Huelsenbeck J. Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. Br. Med. Bull. 2011, 97:17-26.
37. Huelsenbeck S.C., Schorr A., Roos W.P., Huelsenbeck J., Henninger C., Kaina B., Fritz G. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J. Biol. Chem. 2012, 287:38590-38599.
38. Haydont V., Gilliot O., Rivera S., Bourgier C., Francois A., Aigueperse J., Bourhis J., Vozenin-Brotons M.C. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:1471-1482.
39. Yoshida M., Shiojima I., Ikeda H., Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J. Mol. Cell. Cardiol. 2009, 47:698-705.
40. Sandrock K., Bielek H., Schradi K., Schmidt G., Klugbauer N. The nuclear import of the small GTPase Rac1 is mediated by the direct interaction with karyopherin alpha2. Traffic 2010, 11:198-209.
41. Onesto C., Shutes A., Picard V., Schweighoffer F., Der C.J. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol. 2008, 439:111-129.
42. Shutes A., Onesto C., Picard V., Leblond B., Schweighoffer F., Der C.J. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J. Biol. Chem. 2007, 282:35666-35678.
43. Olive P.L., Banath J.P. The comet assay: a method to measure DNA damage in individual cells. Nat. Protoc. 2006, 1:23-29.
44. Grozav A.G., Chikamori K., Kozuki T., Grabowski D.R., Bukowski R.M., Willard B., Kinter M., Andersen A.H., Ganapathi R., Ganapathi M.K. Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity. Nucleic Acids Res. 2009, 37:382-392.
45. Gao Y., Dickerson J.B., Guo F., Zheng J., Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7618-7623.
46. Barker C.R., Hamlett J., Pennington S.R., Burrows F., Lundgren K., Lough R., Watson A.J., Jenkins J.R. The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?. Int. J. Cancer 2006, 118:2685-2693.
47. Sarangi U., Paithankar K.R., Kumar J.U., Subramaniam V., Sreedhar A.S. 17AAG treatment accelerates doxorubicin induced cellular senescence: Hsp90 interferes with enforced senescence of tumor cells. Drug Target Insights 2012, 6:19-39.
48. Cha B., Lim J.W., Kim K.H., Kim H. HSP90beta interacts with Rac1 to activate NADPH oxidase in Helicobacter pylori-infected gastric epithelial cells. Int. J. Biochem. Cell Biol. 2010, 42:1455-1461.
49. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S.L., Galle P.R., Stremmel W., Oren M., Krammer P.H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998, 188:2033-2045.
50. Wells N.J., Hickson I.D. Human topoisomerase II alpha is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur. J. Biochem. 1995, 231:491-497.
51. Shapiro P.S., Whalen A.M., Tolwinski N.S., Wilsbacher J., Froelich-Ammon S.J., Garcia M., Osheroff N., Ahn N.G. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol. Cell. Biol. 1999, 19:3551-3560.
52. Smith L., Watson M.B., O'Kane S.L., Drew P.J., Lind M.J., Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 2006, 5:2115-2120.
53. Mao Y., Desai S.D., Ting C.Y., Hwang J., Liu L.F. 26S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 2001, 276:40652-40658.
54. Turner J.G., Marchion D.C., Dawson J.L., Emmons M.F., Hazlehurst L.A., Washausen P., Sullivan D.M. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009, 69:6899-6905.
55. Wagstaff K.M., Sivakumaran H., Heaton S.M., Harrich D., Jans D.A. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem. J. 2012, 443:851-856.
56. Chikamori K., Grabowski D.R., Kinter M., Willard B.B., Yadav S., Aebersold R.H., Bukowski R.M., Hickson I.D., Andersen A.H., Ganapathi R., Ganapathi M.K. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J. Biol. Chem. 2003, 278:12696-12702.
57. Sandholt I.S., Olsen B.B., Guerra B., Issinger O.G. Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 2009, 20:238-248.
58. Nousiainen M., Sillje H.H., Sauer G., Nigg E.A., Korner R. Phosphoproteome analysis of the human mitotic spindle. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5391-5396.
59. Bryja V., Schambony A., Cajanek L., Dominguez I., Arenas E., Schulte G. Beta-arrestin and casein kinase 1/2 define distinct branches of non-canonical WNT signalling pathways. EMBO Rep. 2008, 9:1244-1250.
60. Cajanek L., Ganji R.S., Henriques-Oliveira C., Theofilopoulos S., Konik P., Bryja V., Arenas E. Tiam1 regulates the Wnt/Dvl/Rac1 signaling pathway and the differentiation of midbrain dopaminergic neurons. Mol. Cell. Biol. 2013, 33:59-70.
61. Barker C.R., McNamara A.V., Rackstraw S.A., Nelson D.E., White M.R., Watson A.J., Jenkins J.R. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res. 2006, 34:1148-1157.
62. Zhang R., Luo D., Miao R., Bai L., Ge Q., Sessa W.C., Min W. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 2005, 24:3954-3963.